Effect of prednisone treatment for 30 and 90 days on bone metabolism in collagen-induced arthritis (CIA) rats

Abstract

Glucocorticoids (GCs) are often prescribed to treat rheumatoid arthritis (RA) in the long term, but there is still controversy in the administration of GCs, mainly because of the adverse reactions such as osteoporosis. Numerous studies have demonstrated that osteoporosis could be induced by GCs in normal rats. However, few experiments have focused on whether osteoporosis could be induced or aggravated by GCs in collagen induced arthritis (CIA) rats. We have investigated bone changes in CIA rats treated with prednisone at 4.5 mg/kg/day for 30 and 90 days by bone histomorphometry, bone mineral density (BMD), micro-CT, biomechanical test, and enzyme-linked immunosorbant assay. We found that high bone turnover osteoporosis was shown in CIA rats. Prednisone treatment for 30 and 90 days improved articular structure and decelerated the degeneration of the femur in CIA rats, but did not improve BMD and bone biomechanics. We conclude that osteoporosis was not aggravated in CIA rats treated with prednisone for 30 and 90 days. On the contrary, prednisone treatment for 30 and 90 days could prevent bone loss of the femur in CIA rats. There was a negative effect on bone metabolism in CIA rats treated with prednisone for 90 days.

Mechanisms of Systemic Osteoporosis in Rheumatoid Arthritis

“…In other words, it is interesting to clarify whether patients suffering from RA also exhibit signs of osteoporosis, which would best be reflected in axial skeleton dysfunction. As a consequence, rodent models of RA are also expected to show signs of such an interrelation, if there is a connection between RA and osteoporosis, which they do [ 17 , 18 ]. Besides, RA is not found in large veterinary species such as in pigs in the way it is found in humans [ 19 ], although in dogs there exists a pathological condition very reminiscent of, but not identical to human RA, namely, immune-mediated polyarthritis (IMPA).…”

Developing cerium modified gold nanoclusters for the treatment of advanced-stage rheumatoid arthritis

“…The symptoms were significantly relieved 10 days after R-DHLA-AuNCs-Ce injection. The recovery is much faster than most drugs for RA symptom relief [ 17 , [22] , [23] , [24] , [25] , [26] , [27] ]. The characteristic contrast photos of heel pads treated with different agents further revealed the superior therapeutic effect of R-DHLA-AuNCs-Ce in advanced RA rats ( Fig.…”

“… GANT61 improve significantly after 2 weeks fibroblast promotes fibroblast apoptosis; soluble in ethanol only [ 26 ] Glucocorticoids improve significantly after 30 days Bone reduces inflammation; water-sodium retention, susceptible to infection. [ 27 ] MTX improve significantly after 13 days CD4 + T cells reduces inflammation; long-term toxicity, myelosuppression [ 25 ] FA-AgNPs improve significantly after 20 days macrophages promotes macrophage polarization; toxic concern [ 17 ] MNP improve significantly after 2 weeks vessels inhibit pannus formation; complex process ​of ​synthetic ​route [ 24 ] Etanercept improve significantly after 2 weeks dendritic cell Symptom relief; long-term toxicity [ 24 ] R-DHLA-AuNCs-Ce improve significantly after 10 days B cells, fibroblast, bone Remarkable treatment effects, low toxicity, cost-effective, efficiently clearance current work Note: FA-AgNPs, folic acid-modified silver nanoparticles; MNP, macrophage-derived microvesicle-coated nanoparticle. …”

Enhancing Prednisone-Based Arthritis Therapy with Targeted IL-27 Gene Delivery

“…Glucocorticoids are often prescribed to treat RA because of their strong anti-inflammatory and immunosuppressive effects [ 5 ]. However, their application must be limited to the short-term due to a risk of adverse events including alterations in bone density once exposure extends past 30 days, for example, in the CIA model of RA [ 6 ]. Prednisolone or prednisone is an established treatment in human RA and acts to suppress inflammation and has been shown to prevent bone damage in the CAIA model of RA [ 6 , 7 ].…”

“…However, their application must be limited to the short-term due to a risk of adverse events including alterations in bone density once exposure extends past 30 days, for example, in the CIA model of RA [ 6 ]. Prednisolone or prednisone is an established treatment in human RA and acts to suppress inflammation and has been shown to prevent bone damage in the CAIA model of RA [ 6 , 7 ]. Recent clinical data support the use of prednisone at low-dose regimens in order to help avoid side effects [ 8 ].…”